Business Context and Reporting Period
This Form 8-K, dated March 1, 2026, reports that Rallybio Corporation (RLYB) has entered into a definitive Agreement and Plan of Merger with Candid Therapeutics, Inc. (Candid), a clinical-stage biotechnology company focused on T-cell engager therapeutics. The transaction involves a reverse merger where a Rallybio subsidiary will merge with Candid, with Candid surviving as a wholly-owned subsidiary. The combined entity is expected to be renamed "Candid Therapeutics, Inc." and will be led by Ken Song, MD, currently the CEO of Candid. Current Rallybio executive officers and directors are expected to tender their resignations upon closing.
Key Financial Metrics and Transaction Structure
The filing details the financial structure of the merger and a concurrent financing event, though it does not report standard operating metrics like revenue or net income for the period.
- Valuation Assumptions: The exchange ratio is based on a pro forma valuation of $47.5 million for Rallybio (assuming $37.5 million in net cash) and $750.0 million for Candid.
- Concurrent Financing: Candid has secured a subscription agreement with accredited investors for an aggregate purchase price of $505.5 million. This financing is a condition precedent to the closing.
- Pro Forma Ownership: Upon closing, pre-Merger Candid equityholders are expected to own approximately 57.55% of the combined company. Pre-Merger Rallybio equityholders are expected to own approximately 3.65%. Investors in the Concurrent Financing are expected to hold approximately 38.80%.
- Liquidity Conditions: Closing requires Rallybio to have net cash of at least $0 and cash and cash equivalents of at least $1,000,000 as of the anticipated closing date.
- Termination Fees: Candid may be required to pay a termination fee of up to $50 million in certain scenarios (e.g., board recommendation change, breach, or alternative transaction within 12 months). Rallybio may be required to pay a termination fee of $1.425 million in specific termination scenarios.
Material Changes and Corporate Actions
The filing outlines several material changes to Rallybio's corporate structure and governance:
- Change of Control: The transaction constitutes a change of control for Rallybio, triggering amendments to employment agreements for key executives (Stephen Uden, Jonathan Lieber, Steven Ryder) to clarify change-in-control benefits.
- Stockholder Matters: Rallybio stockholders must approve the issuance of shares representing more than 20% of outstanding stock, a reverse stock split (ratio to be agreed upon), the name change to "Candid Therapeutics, Inc.," and an increase in authorized shares.
- Contingent Value Rights (CVRs): Existing Rallybio security holders will receive CVRs entitling them to pro rata shares of net proceeds from the disposition of Rallybio's "Legacy Assets" (including payments from Recursion Pharmaceuticals) for a period of one year post-closing. There is no assurance these payments will be made.
- Nasdaq Compliance: The company regained compliance with the $1.00 minimum bid price requirement on February 24, 2026, following a 1-for-8 reverse stock split effective February 6, 2026.
Guidance, Risks, and Contingencies
The filing contains extensive forward-looking statements and identifies significant risks:
- Closing Conditions: The merger is subject to numerous conditions, including stockholder approvals from both companies, Nasdaq listing approvals, effectiveness of the Form S-4, and receipt of at least $200 million in cash proceeds from the Concurrent Financing.
- Regulatory and Legal Risks: Risks include failure to obtain governmental approvals, delays in consummation, and the possibility that the Exchange Ratio adjustments could result in different ownership percentages than anticipated.
- Operational Risks: Risks related to managing operating expenses pending closing and the potential failure of the Concurrent Financing.
- CVR Uncertainty: There is a risk that CVR holders may never receive any proceeds if Legacy Assets are not successfully disposed of or if no payments are received.
Investor Verification Checklist
- Verify the final Exchange Ratio and pro forma ownership percentages once the Form S-4 is filed, as these are subject to adjustments based on final net cash and capitalization.
- Confirm the status of the $505.5 million Concurrent Financing, as the closing is contingent on receiving at least $200 million of these proceeds.
- Review the upcoming Form S-4 and Proxy Statement for detailed risk factors and the specific terms of the reverse stock split.
- Assess the likelihood and timeline for the disposition of Rallybio's Legacy Assets to determine the potential value of the Contingent Value Rights (CVRs).
- Monitor the resignation of current Rallybio management and the transition to the new leadership team led by Ken Song, MD.